Advertisement
Screener

Beam Therapeutics Inc. (BEAM) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

Beam Therapeutics Inc. Increase Decrease In Operating Lease Liability

Beam Therapeutics Inc. (BEAM) reported Increase Decrease In Operating Lease Liability of -$7.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-04

  • Beam Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$3.53M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$3.49M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$3.50M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$3.38M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for fiscal 2025 was -$13.51M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for fiscal 2024 was -$12.95M.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for fiscal 2023 was -$10.17M, a 181.80% decline from fiscal 2022.
  • Beam Therapeutics Inc. increase decrease in operating lease liability for fiscal 2022 was $12.43M, a 22.45% decline from fiscal 2021.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$3.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$7.02M
10-Q · filed 2026-08-04
-$10.52M
derived: sum of 3 quarters · filed 2026-08-04
-$13.91M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$3.49M
10-Q · filed 2026-05-07
-$6.99M
derived: sum of 2 quarters · filed 2026-05-07
-$10.38M
derived: sum of 3 quarters · filed 2026-05-07
-$13.70M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$3.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$6.88M
derived: sum of 2 quarters · filed 2026-02-24
-$10.21M
derived: sum of 3 quarters · filed 2026-08-04
-$13.51M
10-K · filed 2026-02-24
2025-09-30-$3.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$6.71M
derived: sum of 2 quarters · filed 2026-08-04
-$10.01M
10-Q · filed 2025-11-04
-$13.28M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$3.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$6.62M
10-Q · filed 2026-08-04
-$9.90M
derived: sum of 3 quarters · filed 2026-08-04
-$13.33M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$3.30M
10-Q · filed 2026-05-07
-$6.57M
derived: sum of 2 quarters · filed 2026-05-07
-$10.01M
derived: sum of 3 quarters · filed 2026-05-07
-$13.14M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$3.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$6.71M
derived: sum of 2 quarters · filed 2026-02-24
-$9.84M
derived: sum of 3 quarters · filed 2026-02-24
-$12.95M
10-K · filed 2026-02-24
2024-09-30-$3.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$6.57M
derived: sum of 2 quarters · filed 2025-11-04
-$9.68M
10-Q · filed 2025-11-04
-$12.68M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$3.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$6.24M
10-Q · filed 2025-08-05
-$9.25M
derived: sum of 3 quarters · filed 2026-02-24
-$12.36M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31-$3.11M
10-Q · filed 2025-05-06
-$6.12M
derived: sum of 2 quarters · filed 2026-02-24
-$9.22M
derived: sum of 3 quarters · filed 2026-02-24
-$10.73M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$3.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$6.11M
derived: sum of 2 quarters · filed 2026-02-24
-$7.62M
derived: sum of 3 quarters · filed 2026-02-24
-$10.17M
10-K · filed 2026-02-24
2023-09-30-$3.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
-$4.61M
derived: sum of 2 quarters · filed 2024-11-05
-$7.16M
10-Q · filed 2024-11-05
-$8.23M
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30-$1.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
-$4.05M
10-Q · filed 2024-08-06
-$5.12M
derived: sum of 3 quarters · filed 2025-02-25
-$3.97M
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31-$2.55M
10-Q · filed 2024-05-07
-$3.62M
derived: sum of 2 quarters · filed 2025-02-25
-$2.46M
derived: sum of 3 quarters · filed 2025-02-25
$11.66M
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31-$1.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$85.00K
derived: sum of 2 quarters · filed 2025-02-25
$14.21M
derived: sum of 3 quarters · filed 2025-02-25
$12.43M
10-K · filed 2025-02-25
2022-09-30$1.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$15.28M
derived: sum of 2 quarters · filed 2023-11-08
$13.50M
10-Q · filed 2023-11-08
$14.32M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30$14.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$12.35M
10-Q · filed 2023-08-08
$13.16M
derived: sum of 3 quarters · filed 2024-02-27
$16.48M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31-$1.78M
10-Q · filed 2023-05-10
-$960.00K
derived: sum of 2 quarters · filed 2024-02-27
$2.36M
derived: sum of 3 quarters · filed 2024-02-27
$8.14M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31$820.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
$4.14M
derived: sum of 2 quarters · filed 2024-02-27
$9.92M
derived: sum of 3 quarters · filed 2024-02-27
$16.03M
10-K · filed 2024-02-27
2021-09-30$3.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$9.10M
derived: sum of 2 quarters · filed 2022-11-07
$15.21M
10-Q · filed 2022-11-07
2021-06-30$5.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$11.89M
10-Q · filed 2022-08-09
2021-03-31$6.11M
10-Q · filed 2022-05-09
2020-12-31$3.15M
10-K · filed 2023-02-28
2019-12-31-$2.54M
10-K · filed 2022-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
NOVAVAX INC (NVAX)United States$1.748B-6.26